Search
forLearn
5 / 801 resultsResearch
5 / 119 results
research EFFECT OF KANCHNAR TWAK KWATH WITH SHUNTHI CHURNA AND NIMB TAIL NASYA IN HYPOTHYROIDISM: A CASE STUDY
Ayurvedic treatment improved symptoms and reduced TSH levels in a hypothyroidism patient.
research A case study on successful Ayurvedic management of polycystic ovarian syndrome (PCOS) induced infertility
Ayurvedic treatment helped a woman with PCOS become pregnant and have a healthy baby.
research Role of Ayurveda and Yoga in the management of Polycystic Ovarian Syndrome (PCOS)
Combining Ayurveda and Yoga effectively manages PCOS and improves reproductive health.
research A SINGLE CASE STUDY ON AYURVEDIC MANAGEMENT OF HYPOTHYROIDISM
Ayurvedic treatments may help reduce hypothyroidism symptoms.
research Clinical efficacy of Tryushana Churna in management of Hypothyroidism
Tryushana Churna and Kanchanara Guggulu may help improve hypothyroidism symptoms.
Community Join
5 / 1000+ resultscommunity Kintor (Koshine Biomedica) changed their KX-826 pictures on Amazon to a alleged study picture after backlash over fake pictures
Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.
community Koshine comes under two names apparently
The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.